Balanced news tone
News Sentiment
IMTX sentiment intelligence
Immatics NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
57 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-2.7% over one week, +3.2% over four weeks, trend inactive, and near fair-value range.
(IMTX) and the Role of Price-Sensitive Allocations
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
-2.7%
Price reacting lower
Trend fit
Trend inactive
3.2% over four weeks
Fair value
4.5%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
9
Neutral
41
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Traders Daily
Direct company coverage
(IMTX) and the Role of Price-Sensitive Allocations
Immatics N.v. (NASDAQ: IMTX) is showing weak near-term sentiment but strong mid and long-term outlooks, with breakdown currently underway. AI models provide distinct trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe sig
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 14 Jul 2026 05:28
- Source
- Stock Traders Daily
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
AD HOC NEWS
Direct company coverage
Immatics stock holds attention. The focus shifts to its pipeline.
Immatics N.V. (IMTX) is a cancer immunotherapy company with a pipeline focused on T-cell receptor (TCR) based therapies and cell therapy programs, listed on Nasdaq. The company's value is closely tied to its clinical pipeline performance, including trial milestones, safety signal
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 07 Jul 2026 17:21
- Source
- AD HOC NEWS
Stock Traders Daily
Direct company coverage
Responsive Playbooks and the IMTX Inflection
This article analyzes Immatics N.v. (NASDAQ: IMTX), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 59.0:1 risk-reward setup targeting an 18.3% gain against 0.3% risk. The piece provides institutional trading strategies for
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 04 Jul 2026 03:10
- Source
- Stock Traders Daily
TradingView
Direct company coverage
Immatics N.V. Actuals & Estimates (NASDAQ:IMTX)
This article provides detailed financial actuals and analyst estimates for Immatics N.V. (IMTX), including stock price performance, growth trends, future forecasts, and historical highs and lows. It covers income statement, balance sheet, cash flow, and valuation metrics, along w
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 29 Jun 2026 13:14
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Immatics N.V. – NASDAQ:IMTX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 20:54
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Immatics N.V. – NASDAQ:IMTX
This article provides a brief financial overview of Immatics N.V., focusing on its forward price-to-sales ratio. It indicates the stock's performance on the Nasdaq Stock Market under the ticker IMTX and states that the market is currently closed with no trades. The content primar
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 20:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Immatics N.V. – MUN:4A3
This article focuses on the enterprise value to EBIT forward for Immatics N.V., traded on the Munich Stock Exchange under the ticker 4A3. It appears to be a financial data presentation and analysis page from TradingView, providing an overview of the company's financial metrics. T
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 09:39
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Immatics N.V. – NASDAQ:IMTX
The article provides a financial overview of Immatics N.V. (NASDAQ: IMTX), focusing on its price-to-earnings forward metric. It highlights that the market was closed with no trades recorded at the time of the data. The content primarily serves as a placeholder or financial data p
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 17:10
- Source
- TradingView
TradingView
Direct company coverage
IMTX Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and price target for Immatics N.V. (IMTX) stock, including analyst ratings, historical performance, and financial data. It covers frequently asked questions regarding the stock's current price, volatility, market capitalization, earnings,
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Jun 2026 07:11
- Source
- TradingView
TradingView
Direct company coverage
Immatics N.V. Actuals & Estimates (FWB:4A3)
This article provides key financial actuals and estimates for Immatics N.V. (FWB:4A3), including analyst price targets, historical stock performance, and upcoming earnings dates. It also details the company's past quarterly earnings, revenue, net income, EBITDA, and employee coun
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 04:10
- Source
- TradingView
Stock Titan
Direct company coverage
Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award
Immatics N.V. (IMTX) director Adam Leo Stone was granted 48,000 stock options, with an exercise price of $9.09 per share and an expiration date of June 15, 2036. These options will vest 100% on June 16, 2026, marking them as a compensation-related award rather than an open-market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 00:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immatics (IMTX) awards director Alise Reicin 48,000 stock options
Immatics N.V. (IMTX) director Alise Reicin was granted 48,000 stock options as compensation. These options allow her to purchase Immatics ordinary shares at an exercise price of $9.09 per share, expire on June 15, 2036, and will vest 100% on June 16, 2026. This transaction was re
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 00:40
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
Immatics Shareholders Approve All Proposals at June 18, 2026 AGM
Immatics N.V. held its Annual General Meeting on June 18, 2026, where shareholders approved all resolutions, including the adoption of annual accounts, re-election of directors, extension of share repurchase authority, and approval of a 2026 stock option plan. Despite strong shar
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 20 Jun 2026 09:40
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
Immatics (IMTX) director receives 48,000 stock options vesting in 2026
Immatics N.V. (IMTX) director Carter Paul Rutherford was granted 48,000 stock options with an exercise price of $9.09 per share, set to expire on June 15, 2036. These options will vest entirely on June 16, 2026, which is the first anniversary of the grant date. This award is a fo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 23:39
- Source
- Stock Titan
TradingKey
Direct company coverage
Immatics NV (IMTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Immatics NV (IMTXW), focusing on support, resistance, and various indicators including MACD, RSI, KDJ, and moving averages. The analysis suggests a "Sell" signal based on both technical indicators and moving averages due to low volati
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 22:41
- Source
- TradingKey
Stock Titan
Direct company coverage
Immatics N.V. (IMTX) director awarded 48,000 stock options at $9.09
Immatics N.V. director Peter Alan Chambre was granted 48,000 stock options as part of his compensation, allowing him to purchase ordinary shares at an exercise price of $9.09 each. These options will vest 100% on June 16, 2026, and are set to expire on June 15, 2036. This transac
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 09:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares
Immatics N.V. (IMTX) director Eliot Forster has been granted stock options for 48,000 ordinary shares. These options have an exercise price of $9.09 per share and a full vesting date of June 16, 2026, one year from the grant date. The options are set to expire on June 15, 2036.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 08:41
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immatics (IMTX) director receives grant of 48,000 stock options at $9.09
Immatics N.V. director Michael G. Atieh was granted 48,000 stock options with an exercise price of $9.09 per share. These options will vest 100% on June 16, 2026, which is the first anniversary of the grant date, and are set to expire on June 15, 2036. This transaction is classif
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 08:41
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immatics (IMTX) director Mathias Hothum awarded 48,000 options at $9.09 strike
Immatics N.V. (IMTX) Director Mathias Hothum was granted 48,000 stock options at an exercise price of $9.09 per share. These compensation-related options vest 100% on June 16, 2026, and will expire on June 15, 2036. Following this transaction, Hothum holds 48,000 derivative secur
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immatics N.V. (IMTX) 2026 AGM sees all voting items approved and strong turnout
Immatics N.V. held its Annual General Meeting of Shareholders on June 18, 2026, where all agenda voting items were approved by the required majorities. The meeting had a strong turnout, with approximately 64.07% of the company's issued share capital represented. The minutes of th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 20:39
- Source
- Stock Titan
TradingKey
Direct company coverage
Immatics NV (IMTXW) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Immatics NV (IMTXW), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it states that relevant data for these valuation metrics have not yet been disclosed by the company. The article serves primarily as a framewo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 09:10
- Source
- TradingKey
simplywall.st
Direct company coverage
Immatics (IMTX) Stock Looks Expensive After PRAME Platform Update And Cash Runway To 2028
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 07:00
- Source
- simplywall.st
TradingKey
Direct company coverage
Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Immatics NV's (IMTX) dividend and stock split history, noting that no dividends have been distributed in the past five years and no stock split data is available. It presents current stock performance data, including market capitalization and
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 06:09
- Source
- TradingKey
TradingKey
Direct company coverage
Immatics NV (IMTXW) Financial Health: Profitability & Balance Sheet Analysis
This article from TradingKey provides a financial health analysis for Immatics NV (IMTXW), focusing on profitability and its balance sheet. However, the report indicates that relevant financial data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholde
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 01:09
- Source
- TradingKey
TradingKey
Direct company coverage
Immatics NV (IMTXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article concerns the revenue breakdown for Immatics NV (IMTXW), detailing its business segments, regional revenue, and profit contribution. However, the critical financial data required for this breakdown has not yet been disclosed by the company, rendering the specific break
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 14:41
- Source
- TradingKey
TradingKey
Direct company coverage
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Immatics NV (IMTX) has an earnings forecast score of 8.83, ranking 50th in the biotechnology industry. Analysts overwhelmingly recommend a "Buy" for IMTX, with a target price of $17.50, suggesting a potential upside of over 100%. The company expects significant revenue in the upc
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 17 Jun 2026 13:41
- Source
- TradingKey
Seeking Alpha
Direct company coverage
Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Seeking Alpha
markets.businessinsider.com
Direct company coverage
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma, presented at the 2026 ASCO Annual Meeting. The one-time infusion therapy demonstrated significant anti-tumor activity in difficult-to-treat gynecologic
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 15 Jun 2026 18:40
- Source
- markets.businessinsider.com
Eastern Progress
Direct company coverage
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) reported a Q1 loss of $0.50 per share, missing the Zacks Consensus Estimate of a $0.42 loss, and also fell short on revenue expectations with $8.91 million against an estimate that was 38.95% higher. Despite the disappointing quarter, the company's stock has outpe
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 14 Jun 2026 19:09
- Source
- Eastern Progress